Efetividade de Materiais Educacionais para Profissionais de Saúde e População geral Alvo enquanto Medidas Adicionais de Minimização de Risco para Vabysmo®, Eylea® e Lucentis® - O Estudo MARVEL

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/106810
• EU PAS number:
  EUPAS106809
• Study ID:
  106810
• Official title and acronym:
  Efetividade de Materiais Educacionais para Profissionais de Saúde e População geral Alvo enquanto Medidas Adicionais de Minimização de Risco para Vabysmo®, Eylea® e Lucentis® - O Estudo MARVEL
• DARWIN EU® study:
  No
• Study countries:
  Portugal
• Study description:
  Ophthalmological diseases affect all age groups and are increasingly prevalent. Pathologies such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and choroidal neovascularization (CNV) affect the posterior region of the eye, and have common treatment options available. The medicines Vabysmo®, Eylea® and Lucentis® are classified as Antineovascularization Agents and are used in the treatment of these ocular pathologies. Educational programs aim to adequately inform patients about the risks associated with the medicine, and as such their effectiveness must be guaranteed.
• Study status:
  Planned

Research institutions and networks

Institutions

Association for Innovation and Biomedical Research on Light and Image (AIBILI)

Study timelines

Date when funding contract was signed

Planned: 01/09/2023

Study start date

Planned: 15/09/2023

Data analysis start date

Planned: 31/10/2023

Date of final study report

Planned: 30/11/2023

Sources of funding

Other

More details on funding

INFARMED I.P..

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable